Primary intestinal non-Hodgkin's lymphoma: A clinicopathologic analysis of 81 patients

Table 1 Clinicopathologic features n (%)

Characteristics	Number of patients (n = 81)
Gender
Male	58 (71.6)
Female	23 (28.4)
Histology
Low-grade B-cell	18 (22.2)
High-grade B-cell	42 (51.9)
T cell	21 (25.9)
Stage
I~II	66 (81.5)
III~IV	15 (18.5)
Treatment
Surgery alone	3 (3.7)
Nonsurgical	16 (19.8)
Both	61 (75.3)
No	1 (1.2)
Treatment response
Complete remission	56 (69.1)
Partial remission	7 (8.6)
Stable disease	3 (3.7)
Progression	15 (18.5)

Table 2 Sites of origin n (%)

Sites of origin	Number of patients (n = 81)
Duodenum	2 (2.5)
Jejunum	4 (4.9)
Ileum	5 (6.2)
Ileocaecal region	31 (38.3)
Colon	20 (24.7)
Rectum	8 (9.9)
Multiple sites	11 (13.6)

Table 3 Immunohistological phenotypes n (%)

Histologic type	Patients		Total(n = 81)
	Male(n = 58)	Female(n = 23)
B cell	42 (72.4)	18 (78.3)	60 (74.1)
MALT	6 (10.3)	9 (39.1)	15 (18.5)
Follicular lymphoma	3 (5.2)	0 (0.0)	3 (3.7)
Mantle cell lymphoma	3 (5.2)	0 (0.0)	3 (3.7)
DLBCL	27 (46.6)	8 (34.8)	35 (43.2)
Burkitt-like	2 (3.4)	1 (4.3)	3 (3.7)
Burkitt lymphoma	1 (1.7)	0 (0.0)	1 (1.2)
T cell	16 (27.6)	5 (21.7)	21 (25.9)
ETCL	6 (10.3)	1 (4.3)	7 (8.6)
Anaplastic	3 (5.2)	0 (0.0)	3 (3.7)
NK/T	0 (0.0)	1 (4.3)	1 (1.2)
PTCL, NOS	4 (6.9)	1 (4.3)	5 (6.2)
Others	3 (5.2)	2 (8.7)	5 (6.2)

MALT: Marginal zone lymphoma; DLBCL: Diffuse large B-cell lymphoma; ETCL: Enteropathy-type T cell lymphoma; PTCL, NOS: Peripheral T-cell lymphoma, not otherwise specified.

Table 4 Prognostic factors on univariate analysis¹

Characteristics	n = 81	5-year EFS	P value	5-year OS	P value
Age
59 or younger	70	56.1	0.939	68.9	0.852
60 or older	11	56.8		68.4
Gender
Male	58	56.4	0.843	62.3	0.058
Female	23	56.2		85.6
Sites of origin
Small intestine	11	63.6	0.025	80.8	0.219
Ileocaecal region	31	71.0		79.6
Colon	20	54.5		65.2
Rectum	8	37.5		50.0
Multiple sites	11	27.3		46.8
Histology
Low-grade B-cell	18	66.3	0.002	87.5	< 0.001
High-grade B-cell	42	71.3		79.2
T cell	21	23.8		34.8
Stage
I~II	66	58.8	0.387	69.0	0.727
III~IV	15	45.7		71.4
Bulky disease
< 8 cm	54	60.6	0.189	70.1	0.837
≥ 8 cm	27	48.1		67.7
Perforation
Yes	6	28.6	0.074	25.0	0.024
No	75	58.9		72.5
B symptom
Yes	34	55.1	0.768	59.5	0.172
No	47	57.1		75.0
LDH
Elevated	25	34.2	0.010	52.2	0.034
Normal	56	65.9		76.9
Treatment
Surgery-based	64	54.3	0.668	70.9	0.371
Nonsurgical	16	61.9		60.9
Radical surgery
Yes	54	57.7	0.218	70.3	0.599
No	10	40.0		77.8
Period
A	27	51.9	0.594	66.7	0.808
B	54	58.8		71.3

¹Assessed by the log-rank test. EFS: Event-free survival; OS: Overall survival; LDH: Lactate dehydrogenase.

Table 5 Prognostic factors assessed by multivariate analysis¹

Variable	Overall survival		Event-free survival
	Exp(B)	P value	Exp (B)	P value
Pathology (B cell vs T cell)	4.566	0.002	3.833	0.001
LDH (normal 240 U/L)	1.002	0.013	1.003	0.002
Sites of origin	1.370	0.052	1.442	0.010
Gender	2.980	0.089	NE
Perforation	0.835	0.778	0.625	0.438

¹Assessed by Cox multivariate analysis. LDH: Lactate dehydrogenase.

Table 6 Prognostic factors for the subgroups of B-cell lymphomas¹

Variable	Overall survival		Event-free survival
	Exp(B)	P value	Exp (B)	P value
Pathology (subtypes of B cell lymphoma)	1.426	0.174	1.141	0.500
LDH (normal 240 U/L)	3.671	0.127	4.663	0.007
Gender	16.328	0.037	0.804	0.716
Sites of origin	1.604	0.050	1.306	0.151

¹Assessed by Cox multivariate analysis. LDH: Lactate dehydrogenase.